Leukocytes from Patients with Drug-Sensitive and Multidrug-Resistant Tuberculosis Exhibit Distinctive Profiles of Chemokine Receptor Expression and Migration Capacity

Figure 8

Plasma chemokine levels and migration capacity of leukocytes during MDR-TB and DS-TB. Plasma levels of (a) MCP-1, (b) CCL-17, and (c) IP-10 were determined by ELISA in multidrug-resistant (MDR-TB) and drug-sensitive (DS-TB) patients. (HD: , MDR-TB: basal, 1, and 3 moTBt , 8 moTBt , and 16 moTBt . DS-TB: basal and 1 moTBt and 6 moTBt ). Peripheral blood mononuclear cells (PBMCs) from DS-TB and MDR-TB patients isolated before and after anti-TB treatment, evaluated for their ability to migrate in response to (d) MCP-1 and CCL17 or (e) IP-10 and IL-8, using a fluorometric assay (HD: , MDR-TB: (before treatment) and (after treatment), DS-TB: ). The relative fluorescence unit (RFU) is indicative of the magnitude of cellular migration. Bar graphs show . Differences between patient groups and HD at each time point or experimental condition were analyzed using multiple Student’s -test corrected for multiple comparisons using the Sidak–Bonferroni method. , , , and . moTBt: months of antituberculosis treatment.

(a)

(b)

(c)

(d)

(e)